As per a recent study conducted by Zhe Li and colleagues, unilateral percutaneous kyphoplasty (PKP) represents a reliable and safe therapy for osteoporotic vertebral compression fractures (OVCFs) with an intravertebral cleft (IVC). The study involved 309 patients, 266 females and 43 males who obtained PKP treatment from 2010 to 2016. Based on the pre-operative magnetic resonance imaging, the patients were categorized into two groups; OVCFs with IVC and OVCFs without IVC. The posterior wall height (PWH), kyphotic angle (KA) and anterior wall height (AWH) before, after the treatment and at final follow-up were assessed in both groups.
A recent trial published in “Lasers in Medical Science” journal enlightens the role of laser irradiation in managing orthodontic pain during fixed appliance treatment if applied immediately. The pain during orthodontic surgeries is intense, especially for 2 to 4 days after fixed appliance treatment. Therefore, Isabela Parsekian Martins and colleagues assessed the effect of low-level laser therapy on dental pain by conducting a randomized, blinded clinical trial.
Korean Scientists Bae SC and Lee YH carried out the Bayesian network meta-analysis in which they combined the direct and indirect evidence from various randomized controlled trials (RCTs) examining the safety and efficacy of biosimilar + MTX and infliximab + MTX and placebo + MTX (MTX group) in patients with active RA despite treatment with MTX.
As per recent multinational, randomized, double-blind trial published in Mabs Journal, the rituximab (RTX) and its biosimilar CT-P10 appeared to have identical immunogenicity, pharmacodynamics, safety and efficacy measures in managing rheumatoid arthritis (RA). Park W and colleagues conducted the trial within 372 RA patients, out of which 161 patients allocated to CT-P10 group and 211 to RTX group. The change in primary efficacy endpoint from baseline to week 24 was measured through Disease Activity Score 28 (by using joints-C-reactive protein). The AUC from time zero to last measurable concentration, from time zero to infinity and maximum level after two infusions were used to measured co-primary pharmacokinetic endpoints. The safety, immunogenicity and pharmacodynamics were also determined.
According to a recent meta-analysis, Baricitinib, a JAK 1 and 2 inhibitor has proven to manage rheumatoid arthritis (RA) effectively but with no significant safety concerns. JAK (Janus kinases), play an important role in RA pathogenesis and Baricitinib, therefore, plays a crucial role in RA control. There's no question regarding Baricitinib efficacy; however comprehensive efficacy evaluation was still to be assessed.
- 1 of 155